||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Cyprotex Share Discussion Threads
Showing 15301 to 15323 of 15325 messages
|I disagree. They are just capitalist investors like the rest of us. You can partially take part in TRIDENT III if you take a holding in NAS. There's nothing to stop you. If you can't beat them, join them.|
|thats a fair point ... just want to warn anyone not a current holder to look into and then make decision|
|This is known by the long termers here and you'll note the lack of new buying volume.
The strategic review is still awaited.|
|bought 4650 shares about an hour ago for about 150p and just sold for small loss. thoight had researched and was getting pretty excited but not enough ! the loan notes are a killer ... my interp is that circa £8m nominal loan notes are due for redemption in 2018 BUT at 150p share price the redemption costs will be close to £20m+. As a rough rule of thumb the repayment amount will increase by circa £4m for every 30p increase in share price. Now lets assume results are great and share price doubles over next 2 years ... only £60m mkt cap right ? ... company will need to find circa £40m to redeem the £8m of loan notes .... however some are redeemable and some convertible .. whatever either sizeable cash payment and/ or large placing. be warned ... Imo / nai / dyor|
|Reason I bought in a while back was the potential free cash flow.|
|3 simple numbers still amaze me:
FY15 Rev - £15.6m (+>35% YoY)
Gross Margins - >75%
Mcap - £33m
And they have recently launched a biologics offering. Imagine all the business they could generate from companies looking at either new biologic drugs or even biosimilars (like generics for biologics).
Assuming FX tailwind and continued revenue growth, we could be looking at >£20m in revs for a company with a mcap of £33m!! Enough to raise even Warren Buffett's eyebrows?!
Good luck all!
|rrb true about dollar income but also the services CRX provides in the UK look more attractive to Euro denominated pharma's so should be set fair on all fronts.
Also had a trading update 23rd Oct last year so could be one any time.|
|Rrb have no doubt crx know to take maximum advantage of GBP fall.|
|Last year there was a trading update on 23rd November so hopefully a similar date this year.|
|Given sterling weakness and >50% revenues coming from US, next trading update from CRX should please everyone. The only reason the shares aren't motoring ahead is the CLN overhang….|
|Pinkfish, thanks for the reply.|
|Trident III fund predominantly, plus I have a few.
Trident is under NAS, Chris Mills, Harwood Capital etc.
Active in taking SBS private and now JNY. Look AT EKF too.
Anything could happen at CRX, right place, right people, right offerings, right time.
I HOLD some NAS too, sold out of SBS and JNY.|
|Anyone know who holds the convertibles?
4,584,645 of unsecured Convertible Loan Notes due in 30 September 2018 (the "Convertible Notes"). The Convertible Notes are convertible into Ordinary Shares in Cyprotex at a price of 60 pence per share. The Convertible Notes are admitted to the Official List of the Cayman Islands Stock Exchange under the International Securities Identification Number GB00BQ1XZQ04.|
|Why the 2.9 ?
Take over code compliance.|
|Trading update eagerly anticipated. More surprises on the upside and this should continue its upward trajectory. Just a flavour from the interims below,
Ian Johnson, Chairman of Cyprotex PLC, said:
"I am delighted to report that the progress made in 2015 has continued into 2016 and, as previously flagged to the market, we are substantially ahead of our expectations. The growth of the business is global and from an increasingly wide range of industries and sectors. Investment in all sites, which commenced in 2014, continues and is delivering high quality new services which contributed to the increase in revenue in H1 2016. Watertown and both UK sites have grown revenues and consequently operational profitability. The Kalamazoo site has received considerable investment to launch a suite of GLP genotoxicity services which we expect will drive revenue growth for the site in the second half of the year. Of note is the collaboration with Cytocentrics announced in February 2016 where we are developing a full range of ion channel services to meet the expected regulatory changes in cardiac safety testing as a consequence of the CiPA initiative. The second half has started well and the Board looks forward to the remainder of the year with continued confidence."
Methinks the Kalamazoo investment will have a major impact. I'm an investor so DYOR|
|Soon trading up date,very well run company|
|DDI Fusion - excellent, another piece of the jigsaw added.
CRX is looking ever more like a critical node in the Bio-Tech development chain.|
|Brokers are usually paid by the company they work for to give them a pep up now and again unless you are a very large Co with institutional interest.
CRX isn't in need of artificial inflation and isn't quite big enough for insti following.....not yet.
Salty, if you go back about a year on the other BB thread there was some really good research put up by Buywell3, also the CRX blog on their web site gives a good insight as to who they work for, what they do and the legislation they lead the way in
|The doesn't appear to be any broker coverage of CRX. Does anyone know why this would be?|
|I don't really understand the science in the work that crx does but was talking to a colleague who thinks that the new CEO of GSK may be good news for crx. He said this was because she realises the retail opportunity in reduced animal testing on products and that CRX is the market leader in eliminating animal testing for cosmetics. Could anyone more qualified shed any light on this? I can't see anything about the elimination of animal testing on the crx website.
|Register to get INVESTEGATE.CO.UK alerts and you will receive automatically.
The £ is no doubt helping too.
Hard to forecast revenue when so many growth drivers come together at once.|
|Thanks again - life is indeed a continuous learning curve.
Still seems odd that they chose to use this method of dissemination given that many other similar announcements have been made through the standard form of RNS.|
|They don't normally show in the news section on the advfn monitor screen but do appear in the news section on the individual company b/board.|